MDS Virtual Congress 2021 Archives - Page 60 of 132

Identification of a new Homozygous mutation P.R258Q In the gene SYNJ1 of an Algerian consanguine (inbred) Family suffering from early onset atypical Parkinsonism

M. Benmahdjoub, N. Nesrine, S. Bouchetara, A. Bessad, S. Lesage, A. Brice, M. Arezki, S. Kesraoui (Blida, Algeria)
Identifying and Controlling Variability in Digital Health Measures in Parkinson’s disease Clinical Trials

G. Roussos, R. Bhatnagar, J. Burton, J. Cosman, A. Derungs, A. Dowling, K. Fisher, D. Hill, K. Praneeth Kilambi, L. Evers, N. Mehrotra, M. Minchik, M. Muller, T. Ruiz Herrero, S. Sardar, D. Stephenson (London, United Kingdom)
Idiopathic Parkinson’s disease and Sensory disorders: A complication of dopatherpy or an intrinsic feature of the disease?

S. Laroussi, N. Farhat, S. Sakka, R. Boukhdhir, H. Zouari, M. Damak, C. Mhiri (Sfax, Tunisia)
Idiopathic rhombencephalitis involving the substantia nigra followed by rapidly progressive parkinsonian syndrome in a young patient

S. Anis, H. Abu-Amer, T. Fay-Karmon, S. Hassin-Baer (Ramat Gan, Israel)
iFall: Co-producing an instrumented application prototype for falls reporting in Parkinson’s disease

R. Morris, E. Webster, G. Standerline, J. Moore, A. Godfrey, A. Amjad (Newcastle Upon Tyne, United Kingdom)
Immune-Mediated and Mercury Intoxication Ataxias: Anti-GAD Antibodies and Dynamic Stabilometriс Assessment

N. Kolmykova, S. Kiryukhina, D. Labunskiy, E. Razgadova, M. Kustov (Saransk, Russian Federation)
Immune-mediated movement disorder as a Rare Manifestation of a Sarcoma

K. Block, S. Syed, A. Boyle, S. Chandra (Houston, USA)
IMMUNE-MEDIATED MOVEMENT DISORDERS: CLINICAL MANIFESTATIONS, TREATMENT, AND EVOLUTION. A MULTICENTER STUDY

M. Bala, F. Gonzalez, M. Saucedo, L. Bandeo, A. Chertcoff, L. de Francesco, G. Napoli, L. Leon Cejas, P. Bonardo, N. Morera, L. Tschopp, C. Rugilo, C. Calandra, A. Pellene, G. Raina, Z. Salazar, G. Rinaldi, P. Judewicz, J. Rivas, J. Gustavo Jose, D. Ballesteros, M. Tela, F. Gualtieri, J. Amor, C. Esliman, F. Caiza Zambrano, T. Arakaki, N. Garretto, S. Rodriguez, A. Kohler, A. Laffue, O. Martinez, M. Fernandez Pardal, R. Reisin, C. Uribe Roca (Caba, Argentina)
Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations

C. Carroll, A. Lees, J. Ferreira, M. Fonseca, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Plymouth, United Kingdom)
Impact of ALXN1840 on the neurological symptoms of Wilson disease: secondary outcomes of a phase 2, open-label, single-arm study

A. Członkowska, S. Moseley, E. Swenson, D. Bega, P. Hedera, D. Nicholl, J. Bronstein (Warsaw, Poland)
Impact of Covid-19 on Essential Tremor and Dystonic Tremor: experience of an Italian centre

SM. Cartella, C. Terranova, I. Arena, G. Falcone, A. Quartarone, P. Girlanda (Messina, Italy)
Impact of COVID-19 pandemic on development of chronic stress syndromes in patients with Parkinson’s Disease : preliminary results

C. Pauly, M. Hansen, L. Delacour, C. Martin-Gallausiaux, P. Wilmes, R. Krüger, N. Diederich (Esch-Sur-Alzette, Luxembourg)
Impact of device-aided therapies on QoL and Off-time improvement in advanced Parkinson’s Disease patients: Comparative effectiveness results from a Bayesian Network Meta-Analysis

A. Antonini, R. Pahwa, P. Odin, S. Isaacson, A. Merola, L. Wang, P. Kandukuri, Y. Jalundhwala, A. Alobaidi, Y. Bao, C. Zadikoff, J. Parra, L. Bergmann, K. Chaudhuri (Padova, Italy)
Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population

P. Agarwal, R. Barbano, H. Moore, M. Schwartz, A. Zuzek, A. Patel (Kirkland, USA)
Impact of extended quarantine during the COVID-19 pandemic on Parkinson’s disease (PD) patients.

G. Lopez, V. Kurtz, B. Charra, E. Garino, D. Ballesteros (Buenos Aires, Argentina)
Impact of Restless Leg Syndrome (RLS) Severity on Cognitive Function and Depression

K. Mangipudi, C. Adler, N. Zhang, H. Shill, S. Mehta, C. Belden, A. Atri, E. Driver-Dunckley (Scottsdale, USA)
Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1-3 subscales

B. Wyman, S. Hendrix, S. Hennessey, S. Dickson, J. Groves, W. Croft, D. Adams (Draper, USA)
IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH

R. Rose, E. Mitchell, H. Geerts (Sheffield, United Kingdom)
Impact of the postural function сhanges on quality of life and daily activity in patients with Parkinson’s disease during DBS

A. Buniak, S. Likhachev (Minsk, Belarus)
Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study

A. Fasano, C. Spanaki, T. Gurevich, M. Simu, L. Bergmann, J. Parra, P. Sanchez Vega, O. Sanchez-Soliño, N. Kovács (Toronto, Canada)
Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome

D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)
Impaired glucocerebrosidase transport to lysosomes in cultured macrophages derived from blood monocytic cells of patients with Parkinson’s disease associated with mutations in the GBA gene

A. Kopytova, M. Nikolaev, K. Senkevich, D. Bogdanova, A. Izymchenko, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)
Impaired interhemispheric synchrony in Parkinson’s disease patients with impulse control disorders

C. Gan, K. Zhang, Y. Yuan (Nanjing, China)
Impaired ocular tracking in idiopathic REM sleep behavior disorder is associated with gray matter alterations

L. Zhou, J. Chen, C. Jiang, X. Zuo, L. Li, J. Liu (Shanghai, China)
Impaired saccadic inhibition in Huntington mutation carriers

P. Ellmerer, F. Carbone, B. Heim, M. Ritter, M. Peball, S. Spielberger, K. Seppi, A. Djamshidian (Innsbruck, Austria)
Implementing a community-based Parkinson’s Disease Wellness Program during COVID

A. Boddy, M. Lomaglio (Waco, USA)
Implementing a Neuropalliative Care Curriculum for Neurology Residents Focused on Neurodegenerative Diseases

O. Dubaz, J. Hauser (Boston, USA)
Implementing Extension of Community Healthcare Outcomes (ECHO) framework to educate geographically underserved populations in complex Parkinson disease management

L. Neilson, J. Wilhelm, L. Mann, R. Cooper, J. Kraakevik (Portland, USA)
Implementing Systematic Screening and a Treatment Algorithm for Depression in Parkinson’s Disease

C. Marras, A. Naito, J. Beck, R. de Leon, A. Allen, E. Nelson, D. Weintraub, S. Luo, S. Mantri, M. Neault (Toronto, Canada)
Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)
Improvement of excessive daytime sleepiness with low frequency repetitive transcranial magnetic stimulation in Parkinson’s disease: a preliminary sham-controlled study

S. Zhuang, JJ. Wu, X. Gu, LX. Wang, XY. Zhang, CJ. Mao, J. Chen, CF. Liu (Suzhou, China)
Improvement of non-motor symptoms and quality of life after DBS stimulation for refractory dystonia: a one-year follow-up

C. Listik, R. Cury, S. Casagrande, E. Listik, D. Arnaut, N. Santiago, J. Machado, J. de Almeida, E. Barbosa, M. Teixeira, D. de Andrade (Sao Paulo, Brazil)
Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)
Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

T. Stiep, A. Ramirez-Zamora, A. Tröster, R. Jain, L. Chen, M. Okun (Gainesville, USA)
Impulse control disorders in idiopathic REM sleep behaviour disorder and drug-naive Parkinson’s disease

A. Otaiku (Birmingham, United Kingdom)
In vivo relationship between synaptic density and functional connectivity in progressive supranuclear palsy: a multimodal [11C]UCB-J PET and resting state fMRI study.

N. Holland, T. Rittman, T. Cope, A. Perry, S. Jones, G. Savulich, M. Malpetti, T. Fryer, F. Aigbirhio, J. O'Brien, J. Rowe (Cambridge, United Kingdom)
In-vivo cholinergic basal forebrain degeneration and cognition in Parkinson’s disease: imaging results from the COPPADIS study

MJ. Grothe, MA. Labrador-Espinosa, S. Jesús, D. Macías-García, A. Adarmes-Gómez, F. Carrillo, E. Iglesias Camacho, P. Franco-Rosado, F. Roldán Lora, JF. Martín-Rodríguez, M. Aguilar Barberá, P. Pastor, S. Escalante Arroyo, B. Solano Vila, A. Cots Foraster, J. Ruiz Martínez, F. Carrillo Padilla, M. Pueyo Morlans, I. González Aramburu, J. Infante Ceberio, J. Hernández Vara, O. de Fábregues-Boixar, T. Deus Fonticoba, B. Pascual-Sedano, J. Kulisevsky, P. Martínez-Martín, D. Santos-García, P. Mir (Seville, Spain)
Increased free-water in the substantia nigra in idiopathic REM sleep behaviour disorder

L. Zhou, G. Li, Y. Zhang, B. Li, H. Wei, J. Liu (Shanghai, China)
Increased non-motor impairment in Parkinson’s disease with REM-Sleep behaviour disorder; cross-sectional analysis in Luxembourg Parkinson’s Study

L. Pavelka, A. Rauschenberger, P. May, S. Pachchek, Z. Landoulsi, L. Pauly, D. Mcintyre, E. Glaab, R. Krüger (Belvaux, Luxembourg)
Increased prevalence of obsessive-compulsive symptoms in functional movement disorders

L. Novakova, J. Anyz, Z. Forejtová, M. Slovak, T. Rosikova, G. Vechetova, E. Ruzicka, T. Serranova (Prague, Czech Republic)
Increased stroke risk in Parkinson’s disease patients with LRRK2 mutations

D. Macias-Garcia, MT. Periñán, L. Muñoz-Delgado, S. Jesús, MV. Jimenez-Jaraba, D. Buiza-Rueda, M. Bonilla-Toribio, A. Adarmes-Gomez, F. Carrillo, P. Gómez-Garré, P. Mir (Seville, Spain)
Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease

A. Thach, M. Zichlin, N. Kirson, K. Yang, K. Gaburo, E. Pappert, D. Mehta, G. Williams (Marlborough, USA)
Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications

D. Kremens, W. Oertel, R. Pahwa, R. Hauser, C. Lecureuil, R. Johnson, G. Went (Philadelphia, USA)
Induction of Parkinsonian-like changes via targeted down-regulation of astrocytic glutamate transporter GLT-1 in the striatum

C. Ren, K-J. He, J-B. Zhang, L-G. Dong, F. Wang, C-F. Liu (Suzhou, China)
Influence of deep brain stimulation on premotor-motor interaction in patients with Parkinson’s disease

M. Pauly, M. Barlage, F. Hamami, J. Steinhardt, J. Baarbe, S. Tran, H. Hanssen, V. Tadic, N. Brueggemann, R. Chen, A. Muenchau, T. Baeumer, A. Weissbach (Luebeck, Germany)
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

B. Mohamed, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Cardiff, United Kingdom)
Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)
Influence of Levodopa on Archimedes Spiral Drawings in Idiopathic Parkinson’s Disease

L. Pillai, A. Glover, T. Virmani (Little Rock, USA)
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)
Informant vs. Self-ratings of Activities of Daily Living in Parkinson’s Disease patients

S. Becker, S. Nussbaum, K. Michaelis, K. Brockmann, I. Liepelt-Scarfone (Calgary, Canada)
Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

M. Zeissler, R. Windle, K. Raphael, G. Rafaloff, K. Mcfarthing, H. Matthews, C. Carroll (Plymouth, United Kingdom)
Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease

JB. Zhang, C. Ren, KJ. He, F. Wang, CF. Liu (Suzhou, China)
Initial longitudinal analyses of objectively assessed cognitive functional abilities in a cohort with Parkinson’s disease

S. Holden, A. Fought, K. Olson, N. Lopez-Esquibel, T. Carlisle, L. Medina (Aurora, USA)
Injections of incobotulinumtoxinA at intervals less than 10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard injection intervals

C. Comella, R. Hauser, S. Isaacson, D. Truong, O. Oguh, J. Hui, E. Molho, M. Brodsky, E. Furr-Stimming, G. Comes, M. Hast, D. Charles (New Philadelphia, USA)
Insulin resistance and Parkinson’s disease

E. Hogg, H. Maghzi, P. Mcelhinney, E. Tan, T. Wu, H. Pomeroy, D. Dey, G. Pagano, M. Tagliati (Los Angeles, USA)
Integrated Multi-omics of the Gut Microbiome Reveal 2-Hydroxypyridine as a Novel Molecule Relevant to Parkinson’s Disease Pathogenesis

V. Aho, JP. Trezzi, C. Jäger, S. Schade, C. Trenkwalder, A. Janzen, U. Heins-Marroquin, C. Linster, G. Gomez Giro, J. Schwamborn, T. Kitami, M. Thomas, K. Schmit, C. Martin-Gallausiaux, M. Buttini, M. Mittelbronn, W. Oertel, B. Mollenhauer, P. Wilmes (Esch-Sur-Alzette, Luxembourg)
Intensive rehabilitation program for patients with functional motor disorders: 3-years’ experience.

B. Martín Rojo, L. Martínez López, P. Rada Romero, C. Vicente Torcal, M. García Ibañez, B. Borda Nuin, M. Sanz Amador, C. Delgado Suarez, M. Kurtis Urra, I. Pareés Moreno (Madrid, Spain)
Inter-Electrode Distance influences the phase-amplitude coupling (PAC) of Bipolar Subthalamic Local Field Potentials Recordings in Parkinson’s Disease

A. Averna, M. Marceglia, M. Arlotti, M. Locatelli, P. Rampini, A. Priori, T. Bocci (Milano, Italy)
Inter-Electrode Distance Influences the Spectral Power of Subthalamic Bipolar Local Field Potentials Recordings in Parkinson’s Disease

A. Averna, S. Marceglia, M. Arlotti, M. Locatelli, P. Rampini, A. Priori, T. Bocci (Milan, Italy)
Interest of optical coherence tomography in Parkinson’s disease

N. Chtaou, S. Bouchal, A. El Midaoui, Z. Souirti, M F. Belahsen, M. Bouhlal (Fez, Morocco)
Intergenerational repeat instability of TTTCA expansions in SAMD12 might be the major cause of the genetic anticipation in familial cortical myoclonic tremor with epilepsy

ZD. Cen, XH. Chen, HT. Wang, DH. Yang, F. Zhang, Y. Chen, S. Chen, LB. Wang, P. Liu, F. Xie, B. Wang (Hangzhou, China)
INTERLEUKIN 4 (IL-4),INTERLEUKIN 1α (IL-1α) AND CORTISOL SERUM LEVELS IN PARKINSON’S DISEASE PATIENTS UNDERGOING DANCE THERAPY

K. Marques, J. Duarte, G. Bahia, B. Dos Santos-Lobato, L. Krejcová, C. Bahia (Belém, Brazil)
Intermittent theta burst stimulation over primary motor cortex ameliorates physical fatigue in Parkinson’s disease patients

J. Gómez-Feria, S. Blanco-Trejo, S. Jesús, L. Chirosa-Rios, I. Chirosa-Rios, JF. Martín-Rodríguez, P. Mir (Sevilla, Spain)
INTERMUSCULAR COHERENCE WITHIN THE UPPER LIMB IN PERSONS WITH ESSENTIAL TREMOR

D. Free, I. Syndergaard, A. Pigg, S. Muceli, J. Thompson-Westra, K. Mente, C. Maurer, D. Haubenberger, M. Hallett, D. Farina, S. Charles (Provo, USA)
Interrogating Parkinson’s disease associated mutations at single cell resolution

EGY. Chew, YJ. Heng, M. Lian, M. Tandiono, E. Dempster, S. Policicchio, J. Mill, R. Reynolds, JN. Foo (Singapore, Singapore)
Intrasubject subcortical quantitative referencing to make quantitative MRI sensitive to Parkinson’s disease

L. Khedher, JM. Bonny, F. Durif (Clermont Ferrand, France)
Investigating LRRK2 and GBA genetic variability in underrepresented populations

C. Paisan-Ruiz, V. Katsnelson, N. Urval, R. Ortega, A. Debebe, I. Peter, S. Bressman, R. Saunders-Pullman (New York, USA)
Investigation of the consultation status and clinical symptoms of patients with Parkinson’s disease after the spread of COVID-19

M. Iijima, R. Morimoto, K. Kitagawa (Tokyo, Japan)
Is cognitive performance related to motor performance among people with Parkinson disease?

K. Rawson, L. Tueth, T. Baker, J. Cavanaugh, C. Colon-Semenza, T. Deangelis, D. Fulford, T. Nordahl, C. Thomas, M. Lavalley, M. Saint-Hilaire, J. Zajac, T. Ellis, G. Earhart (St. Louis, USA)
Is dopamine replacement therapy an addictive drug?

V. Fleury, E. Pirondini, C. Provins, D. Benis, D. Vandeville, P. Krack (Geneva, Switzerland)
IS FATIGUE ASSOCIATED WITH BALANCE IN PARKINSON’S DISEASE?

M. Terra, I. Caramaschi, H. Araújo, R. de Souza, T. da Silva, T. Nascimento, V. Probst, S. Smaili (Londrina Pr, Brazil)
Is Generalized and Segmental Dystonia Accompanied by Impairments of the Dopaminergic System?

J. Ikezawa, F. Yokochi, R. Okiyama, S. Kumada, M. Tojima, T. Kamiyama, T. Hanakawa, H. Matsuda, F. Tanaka, Y. Nakata, E. Isozaki (Fuchu, Japan)
Is past use of statins associated with lower incidence of Parkinson’s disease?

TTH. Nguyen, A. Fournier, F. Artaud, E. Courtois, S. Escolano, P. Tubert-Bitter, MC. Boutron, G. Severi, E. Roze, I. Degaey, M. Canonico, I. Ahmed, A. Thiébaut, A. Elbaz (Villejuif, France)
Is the association between cigarette smoking and Parkinson disease causal? A Mendelian Randomization study.

C. Domenighetti, PE. Sugier, A. Ashokkumar Sreelatha, C. Schulte, S. Grover, O. Mohamed, B. Portugal, P. May, D. Bobbili, M. Radivojkov-Blagojevic, P. Lichtner, R. Krüger, T. Gasser, M. Sharma, A. Elbaz (Villejuif Cedex, France)
IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW

C. Kalva-Filho, M. Kuroda, E. Costa, J. Corradini, F. Barbieri (Bauru, Brazil)
Is there a place for virtual support groups for Parkinson’s disease in Africa? Lessons from the Covid-19 pandemic

N. Fothergill-Misbah, J. Price, O. Thomas, J. Okeno, R. Walker, L. Ebenezer (Newcastle Upon Tyne, United Kingdom)
Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)